mRNA Victoria and BioMelbourne Network, are hosting a series of four lectures in the first half of 2023 for the Victorian RNA community.A networking session for attendees to foster new connections and nurture existing ones with each other will conclude each lecture event. Refreshments will be provided.These lectures present an opportunity for leading specialists in the RNA sector to share their knowledge with the local RNA community. The accompanying networking session following each lecture is also an opportunity to foster connections between researchers, industry and government so that synergies and collaboration opportunities can be discovered.
Lecture One – Introduction to the Intellectual Property landscape, the product development pathway and leveraging existing capabilities in the development of new RNA therapeutics | 7 February, 5pm – 7pm (Sold out)
Lecture Two – Fireside Chat with Professor Robert Langer, co-founder of Moderna, Institute Professor at MIT | 21 March, 8am – 11am
Lecture Three – Exploring the Clinical Trials Landscape | 2 May, 5pm – 7pm
Lecture Four – Enabling RNA Technology | 6 June, 5pm – 7pm
Introduction to the Intellectual Property landscape, the product development pathway and leveraging existing capabilities in the development of new RNA therapeutics
Rachel Sciascia, Legal Practitioner Director, Deloitte Legal
Dr. Patricia Vietheer, Director, R&D Strategy & Planning, Biointelect
Dr. James Patterson, Executive Director Manufacturing, mRNA Victoria
Lecture 1 event recording:
0:04 Welcome | Jeff Malone, CEO, BioMelbourne Network
4:00 Opening Remarks | Michael Kapel, CEO, mRNA Victoria
7:15 Lecture 1 Introduction | Dr James Patterson, Executive Director Manufacturing, mRNA Victoria
9:05 The IP Landscape | Rachel Sciascia, Legal Practitioner Director, Deloitte Legal
23:40 The Product Development Pathway | Dr Patricia Vietheer, Director, R&D Strategy & Planning, Biointelect
44:50 Leveraging Existing Capabilities | Dr James Patterson, Executive Director Manufacturing, mRNA Victoria
1:00:45 Panel and Q&A
About mRNA Victoria
mRNA Victoria is responsible for leading the Victorian Government’s commitment to establish a world-class mRNA and RNA industry in Victoria, by supporting supply chain, research and development for pre and clinical research, commercialisation and manufacturing investments.Its role is to identify key capabilities, gaps, opportunities and lead the Victorian Government’s engagement, investment and partnerships with domestic and international companies, researchers and stakeholders to build RNA capability.
With degrees in law and science, Rachel has extensive experience in intellectual property, information and communications technology and corporate and commercial law matters. Rachel acts for a broad range of clients across large multi-national corporations, government, statutory bodies and public and private companies.
Rachel is particularly well-known for her expertise in drafting, negotiating and advising on the protection, commercialisation and use of all types of intellectual property, particularly involving complex combinations of technologies.
She is an expert in corporate structures and commercial arrangements involving the development and exploitation of intellectual property.
Rachel has been named in a range of legal lists for her intellectual property expertise.
Dr Patricia Vietheer, Director, R&D Strategy & Planning, Biointelect
Patricia Vietheer has over 18 years of scientific experience in the Life Sciences industry. She holds a Bachelor of Science degree with First Class Honours from University of Queensland and a PhD in Microbiology at Monash University. She also holds an MBA majoring in Strategy & Planning at Deakin University. In 2015, Patricia completed the Molecules to Medicine Internship on Commercialization.
A specialist in infectious diseases, molecular biology and viral immunology, Patricia’s career began in the research laboratory working on the preclinical evaluation of a versatile vaccine platform collaborating with industry. She has since held a range of roles in research; business development, project management and program development where she has helped translate scientific ideas into public health solutions. Patricia’s deep experience in early-stage preclinical R&D especially in vaccine development, technology transfer and in vivo animal studies, has been instrumental in project planning and execution often working in cross-discipline, multi-country projects driving projects towards successful outcomes. At Biointelect, Patricia supports clients with their commercialisation strategies and streamlining their path to market.
Patricia has been a recipient of multiple awards including the NHMRC Dora Lush BioMedical Award, Australian Defence Force Prince of Wales Award and the Australian Centre for HIV & Hepatitis Virology Young Investigator’s Award. She has made substantial contribution to numerous granted patents, co-authored multiple scientific publications in peer-reviewed journals and has presented at numerous national and international conferences.
Dr James Patterson, Executive Director Manufacturing, mRNA Victoria
James Patterson is the Executive Director of Manufacturing at mRNA Victoria. James is responsible for delivering the mRNA development and manufacturing capabilities to support the Victorian ecosystem. He has expertise in small molecule, monoclonal antibody and oligonucleotide preclinical development, evaluating pharmaceutical investment opportunities, leading matrix teams, and managing product lifecycle activities.
Prior to joining the public sector, James worked in the pharmaceutical industry for over 20 years. James has a PhD in pharmaceutical science from Otago University. This opportunity was supported by the Otago University/Vernon Tews Educational Trust scholarship to conduct an industrial placement at GlaxoSmithKline in the UK. Following graduation, James worked at GSK as a scientist across UK and US markets as a principal investigator. James relocated to Melbourne in 2010 and has worked as Technical Director for Business Development for GSK across several markets in Asia Pacific. James also serves as a peer reviewer for several scientific journals.